New Liquid ready-to-use Tumour Marker Control available now from Randox

The new Randox Acusera multi-analyte Liquid Tumour Marker Control covers a total of 15 commonly tested and esoteric cancer antigens and tumour markers. The addition of assayed target values enables laboratories to effectively monitor both accuracy and precision.

As a liquid ready-to-use control the material is highly convenient and easy for laboratory staff to use. The liquid stable nature not only eliminates the need for reconstitution but reduces the amount of human handling necessary and allows the material to be shipped and stored conveniently at 2-8oC.

Like all Randox immunoassay controls the serum is 100% human in origin providing a matrix similar to the patient sample but also reducing antibody interference and the possibility of control values shifting after changing reagent batch. Three distinct and clinically significant levels of control are available with analytes present at desirable levels. The convenient 6 x 3ml pack size and refrigerated open vial stability of 30 days for all analytes helps to increase laboratory efficiency while keeping waste and costs to a minimum.

As a true third party control laboratories can use the Acusera liquid tumour marker control to independently assess the performance of their tumour marker testing. Fully assayed, instrument specific target values are generated via a number of external laboratories and are provided for many common clinical chemistry and immunoassay systems.

The Randox Acusera liquid tumour marker control is compatible for use with Acusera 24.7, a web based inter-laboratory data management programme. With 24-7 users benefit from our extensive range of data management tools and gain access to peer group data from thousands of laboratories worldwide. Acusera 24.7 uniquely updates peer group data every 24 hours giving laboratories access to the most up to date information available.

For more information please visit www.randox.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Randox Laboratories Ltd.. (2012, May 15). New Liquid ready-to-use Tumour Marker Control available now from Randox. News-Medical. Retrieved on November 24, 2024 from https://www.news-medical.net/news/20120515/New-Liquid-ready-to-use-Tumour-Marker-Control-available-now-from-Randox.aspx.

  • MLA

    Randox Laboratories Ltd.. "New Liquid ready-to-use Tumour Marker Control available now from Randox". News-Medical. 24 November 2024. <https://www.news-medical.net/news/20120515/New-Liquid-ready-to-use-Tumour-Marker-Control-available-now-from-Randox.aspx>.

  • Chicago

    Randox Laboratories Ltd.. "New Liquid ready-to-use Tumour Marker Control available now from Randox". News-Medical. https://www.news-medical.net/news/20120515/New-Liquid-ready-to-use-Tumour-Marker-Control-available-now-from-Randox.aspx. (accessed November 24, 2024).

  • Harvard

    Randox Laboratories Ltd.. 2012. New Liquid ready-to-use Tumour Marker Control available now from Randox. News-Medical, viewed 24 November 2024, https://www.news-medical.net/news/20120515/New-Liquid-ready-to-use-Tumour-Marker-Control-available-now-from-Randox.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
RX daytona+ provides high quality testing on compact easy to use platform